Results 31 to 40 of about 2,000 (177)

Lenacapavir: First Approval

, 2022
   Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Julia Paik is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Julia Paik (6912664)
core   +1 more source

PROCESS FOR THE PREPARATION OF AMORPHOUS LENACAPAVIR SODIUM [PDF]

The present disclosure relates to preparation of amorphous Lenacapavir sodium by spray drying ...
Anonymous,
core   +4 more sources

Lenacapavir at the Spatiotemporal Limit: Tissue Pharmacokinetics, Pharmacokinetic Tail Dynamics, and the Emergence of Capsid Resistance in Long-Acting HIV Prevention. [PDF]

Clin Pharmacol
Background: Lenacapavir (LEN), a first-in-class HIV-1 capsid inhibitor administered subcutaneously twice yearly, has demonstrated near-perfect efficacy in Phase 3 trials, generating justified enthusiasm for its potential to reconfigure HIV prevention ...
Chris-Uchendu HC, Olwit G, Atuhaire A, Matovu I, Kirumira HN, Sasiita PK, Odongo L, Mutekanga A, Nkwanga J.   +8 more
europepmc   +2 more sources

Lenacapavir and global HIV prevention: a breakthrough at risk of leaving millions behind. [PDF]

Ann Med Surg (Lond)
In June 2025, the FDA approved Lenacapavir, a twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), following striking trial results showing near-perfect efficacy. This long-acting injectable represents a game-changing innovation, promising to
Miteu GD.
europepmc   +2 more sources

Breakthrough Design of Highly Potent Antivirals Against Wild‐Type HIV‐1 and Lenacapavir‐Resistant M66I Variant

Angewandte Chemie, EarlyView.
Lenacapavir, the first‐in‐class drug targeting HIV‐1 capsid, is a breakthrough drug in HIV‐1 treatment and prophylaxis. However, a single M66I mutation confers complete viral resistance to lenacapavir. We report herein the design and synthesis of innovative R2 analogs demonstrating low nM potency against HIV‐1 M66I and excellent pharmacokinetics in ...
Nicolas Jamey, D. M. Nirosh Udayanga, Huanchun Zhang, Roshan Katekar, Wei Xie, Shreya M. Ravichandran, Xinyong Cai, Zachary C. Lorson, William M. McFadden, Won Hee Ryu, Jiashu Xie, Karen A. Kirby, Stefan G. Sarafianos, Zhengqiang Wang   +13 more
wiley   +2 more sources

Genetic diversity of capsid protein (p24) in human immunodeficiency virus type-1 (HIV-1) variants circulating in the Russian Federation

Вопросы вирусологии, 2023
Introduction. The human immunodeficiency virus (HIV) protein p24 plays an important role in the life cycle of the virus, and also is a target for diagnostic tests and for new antiretroviral drugs and therapeutic vaccines.
A. I. Kuznetsova, I. M. Munchak, A. V. Lebedev, A. S. Tumanov, K. V. Kim, A. A. Antonova, E. N. Ozhmegova, A. Yu. Pronin, E. V. Drobyshevskaya, E. V. Kazennova, M. R. Bobkova   +10 more
doaj   +1 more source

Efficacy and safety of long-acting lenacapavir for HIV treatment and prevention: A systematic review of randomized trials

International Journal of Infectious Diseases
Background: Lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor enabling treatment and prevention with reduced reliance on daily oral adherence. Evidence from randomized trials across indications remains fragmented.
Blessed Takunda Mukuhlani, Rufin Kouassi ASSARÉ   +1 more
doaj   +1 more source

Lenacapavir disrupts HIV-1 core integrity while stabilizing the capsid lattice

Proceedings of the National Academy of Sciences of the United States of America
Significance Capsid inhibitor lenacapavir (GS-6207; LEN) binds to HIV-1 cores and potently blocks virus replication. We evaluated LEN’s effects on HIV-1 capsids using two labeling methods: GFP content marker (cmGFP) to measure capsid integrity and GFP ...
Chenglei Li, Ryan C. Burdick, Rokeya Siddiqui, S. Janaka, Ru-Ching Hsia, Wei-Shau Hu, Vinay K. Pathak   +6 more
semanticscholar   +1 more source

Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis

xi, 47 p.This publication provides evidence-based recommendations on the use of long-acting injectable lenacapavir for HIV prevention and on HIV testing strategies to support the delivery of long-acting pre-exposure prophylaxis (PrEP).
World Health Organization
semanticscholar   +2 more sources

Genetic Diversity in the Capsid Protein-Coding Region of HIV-1 Circulating in Benguela, Angola: Implications for Primary Resistance to the Novel Capsid Inhibitor Lenacapavir

Viruses
In 2023, the HIV-1 pandemic claimed around 630,000 lives worldwide due to AIDS-related complications. Its burden is significantly heavier in Sub-Saharan Africa, where an increased HIV-1 genetic diversity is common, which increases the risk of resistance ...
Gonçalo Queirós, Lesya Yefimenko, Filomena M. Pereira, João Piedade   +3 more
doaj   +1 more source